The Experts below are selected from a list of 4245 Experts worldwide ranked by ideXlab platform

Nicolas Kalach - One of the best experts on this subject based on the ideXlab platform.

  • Randomized Trial of a Yogurt-type Amino Acid-Based Formula in Infants and Children With Severe Cow's Milk Allergy.
    Journal of pediatric gastroenterology and nutrition, 2018
    Co-Authors: François Payot, Alain Lachaux, Florent Lalanne, Nicolas Kalach
    Abstract:

    OBJECTIVES Evaluation of a spoon-fed Amino Acid-Based Formula (AAF) with a yogurt-type texture compared to the reference oral liquid Formula (Neocate). METHODS Phase III/IV, prospective, randomized (1:1), open-label, multicenter study in infants/young children (6-36 months) with severe cow's milk protein allergy (CMA) who had consumed AAF for ≥1 month before the study. Patients received reference+test Formula (Neocate with a yogurt-type texture for spoon-feeding: group 1) or reference Formula (group 2) for 28 days. The study Formulae were integrated into the patients' usual daily diet. Efficacy on Day 0, 14, and 28 was assessed primarily in terms of symptoms associated with CMA. The evolution of symptoms, amount of Formula consumed, nutritional and energy intake, anthropometric data, and tolerability were also assessed. RESULTS The incidence of CMA symptoms was similar in each group (P > 0.05) on day 0, 14, and 28. For specific symptoms, there was little change from day 0 and no significant difference between groups for incidence on day 0 or evolution at day 14 or 28. There was no difference in Formula consumption (day 0-day 28) between groups (P = 0.90), but nutritional value was generally higher for group 1 and calcium intake was statistically higher for group 1 (P 

  • Randomized Trial of a Yogurt-type Amino Acid-Based Formula in Infants and Children With Severe Cow's Milk Allergy
    Journal of Pediatric Gastroenterology and Nutrition, 2018
    Co-Authors: François Payot, Alain Lachaux, Florent Lalanne, Nicolas Kalach
    Abstract:

    Objectives:Evaluation of a spoon-fed Amino Acid-Based Formula (AAF) with a yogurt-type texture compared to the reference oral liquid Formula (Neocate).Methods:Phase III/IV, prospective, randomized (1:1), open-label, multicenter study in infants/young children (6-36 months) with severe cow's milk protein allergy (CMA) who had consumed AAF for 1 month before the study. Patients received reference+test Formula (Neocate with a yogurt-type texture for spoon-feeding: group 1) or reference Formula (group 2) for 28 days. The study Formulae were integrated into the patients' usual daily diet. Efficacy on Day 0, 14, and 28 was assessed primarily in terms of symptoms associated with CMA. The evolution of symptoms, amount of Formula consumed, nutritional and energy intake, anthropometric data, and tolerability were also assessed.Results:The incidence of CMA symptoms was similar in each group (P\textgreater0.05) on day 0, 14, and 28. For specific symptoms, there was little change from day 0 and no significant difference between groups for incidence on day 0 or evolution at day 14 or 28. There was no difference in Formula consumption (day 0-day 28) between groups (P=0.90), but nutritional value was generally higher for group 1 and calcium intake was statistically higher for group 1 (P\textless0.05). Weight-for-height, weight-for age, and body mass index-for-age z scores were higher for group 1 than group 2 (P\textless0.05). Both Formulae were well tolerated.Conclusions:There was no difference in efficacy, Formula consumption, and tolerability between the new spoon-fed yogurt-type AAF Formula and the reference Formula, whereas significantly higher calcium intake was achieved with the new Formula.

François Payot - One of the best experts on this subject based on the ideXlab platform.

  • Randomized Trial of a Yogurt-type Amino Acid-Based Formula in Infants and Children With Severe Cow's Milk Allergy.
    Journal of pediatric gastroenterology and nutrition, 2018
    Co-Authors: François Payot, Alain Lachaux, Florent Lalanne, Nicolas Kalach
    Abstract:

    OBJECTIVES Evaluation of a spoon-fed Amino Acid-Based Formula (AAF) with a yogurt-type texture compared to the reference oral liquid Formula (Neocate). METHODS Phase III/IV, prospective, randomized (1:1), open-label, multicenter study in infants/young children (6-36 months) with severe cow's milk protein allergy (CMA) who had consumed AAF for ≥1 month before the study. Patients received reference+test Formula (Neocate with a yogurt-type texture for spoon-feeding: group 1) or reference Formula (group 2) for 28 days. The study Formulae were integrated into the patients' usual daily diet. Efficacy on Day 0, 14, and 28 was assessed primarily in terms of symptoms associated with CMA. The evolution of symptoms, amount of Formula consumed, nutritional and energy intake, anthropometric data, and tolerability were also assessed. RESULTS The incidence of CMA symptoms was similar in each group (P > 0.05) on day 0, 14, and 28. For specific symptoms, there was little change from day 0 and no significant difference between groups for incidence on day 0 or evolution at day 14 or 28. There was no difference in Formula consumption (day 0-day 28) between groups (P = 0.90), but nutritional value was generally higher for group 1 and calcium intake was statistically higher for group 1 (P 

  • Randomized Trial of a Yogurt-type Amino Acid-Based Formula in Infants and Children With Severe Cow's Milk Allergy
    Journal of Pediatric Gastroenterology and Nutrition, 2018
    Co-Authors: François Payot, Alain Lachaux, Florent Lalanne, Nicolas Kalach
    Abstract:

    Objectives:Evaluation of a spoon-fed Amino Acid-Based Formula (AAF) with a yogurt-type texture compared to the reference oral liquid Formula (Neocate).Methods:Phase III/IV, prospective, randomized (1:1), open-label, multicenter study in infants/young children (6-36 months) with severe cow's milk protein allergy (CMA) who had consumed AAF for 1 month before the study. Patients received reference+test Formula (Neocate with a yogurt-type texture for spoon-feeding: group 1) or reference Formula (group 2) for 28 days. The study Formulae were integrated into the patients' usual daily diet. Efficacy on Day 0, 14, and 28 was assessed primarily in terms of symptoms associated with CMA. The evolution of symptoms, amount of Formula consumed, nutritional and energy intake, anthropometric data, and tolerability were also assessed.Results:The incidence of CMA symptoms was similar in each group (P\textgreater0.05) on day 0, 14, and 28. For specific symptoms, there was little change from day 0 and no significant difference between groups for incidence on day 0 or evolution at day 14 or 28. There was no difference in Formula consumption (day 0-day 28) between groups (P=0.90), but nutritional value was generally higher for group 1 and calcium intake was statistically higher for group 1 (P\textless0.05). Weight-for-height, weight-for age, and body mass index-for-age z scores were higher for group 1 than group 2 (P\textless0.05). Both Formulae were well tolerated.Conclusions:There was no difference in efficacy, Formula consumption, and tolerability between the new spoon-fed yogurt-type AAF Formula and the reference Formula, whereas significantly higher calcium intake was achieved with the new Formula.

Riccardo Troncone - One of the best experts on this subject based on the ideXlab platform.

  • Tolerance to a new free Amino Acid-Based Formula in children with IgE or non-IgE-mediated cow’s milk allergy: a randomized controlled clinical trial
    BMC Pediatrics, 2013
    Co-Authors: Roberto Berni Canani, Rita Nocerino, Linda Cosenza, Margherita Di Costanzo, A Passariello, Gianluca Terrin, L Leone, Riccardo Troncone
    Abstract:

    BackgroundAmino Acid-Based Formulas (Aaf) are increasingly used in children with cow’s milk allergy (CMA). To be labeled hypoallergenic these Formulas must demonstrate in clinical studies that they don’t provoke reactions in 90% of subjects with confirmed CMA with 95% confidence when given in prospective randomized, double-blind, placebo-controlled challenge (DBPCFC) trials. The majority of available safety data on Aaf derived from patients with IgE-mediated CMA. Considering substantial differences in the immunologic mechanism and clinical presentation of non-IgE-mediated CMA it’s important to investigate the hypoallergenicity of these Formulas also in these patients. We prospectively assessed the tolerance to a new commercially available Aaf in children affected by IgE- or non-IgE-mediated CMA.MethodsConsecutive patients affected by IgE- or non-IgE-mediated CMA, aged ≤ 4 years, were enrolled. DBPCFC was carried out with increasing doses of the new Aaf (Sineall, Humana, Milan, Italy), using validated Aaf as placebo. Faecal concentrations of calprotectin (FC) and eosinophilic cationic protein (ECP) were monitored.ResultsSixty patients (44 male, 73.3%, median age 37, 95%CI 34.5–39.6 months, IgE-mediated CMA 29, 48.3%) were enrolled. At the diagnosis clinical symptoms were gastrointestinal (46.6%), cutaneous (36.6%), respiratory (23.3%), and systemic (10.0%). After DBPCFC with the new Aaf, no patient presented early or delayed clinical reactions. Faecal concentration of calprotectin and of ECP remained stable after the exposure to the new Aaf.ConclusionsThe new Aaf is well tolerated in children with IgE- or non-IgE-mediated CMA, and it could be used as a safe dietotherapy regimen for children with this condition.Trial registrationThe trial was registered in the ClinicalTrials.gov Protocol Registration System (ID number: NCT01622426).

  • Tolerance to a new free Amino Acid-Based Formula in children with IgE or non-IgE-mediated cow’s milk allergy: a randomized controlled clinical trial
    BMC pediatrics, 2013
    Co-Authors: Roberto Berni Canani, Rita Nocerino, Linda Cosenza, Margherita Di Costanzo, A Passariello, Gianluca Terrin, Ludovica Leone, Riccardo Troncone
    Abstract:

    Background Amino Acid-Based Formulas (Aaf) are increasingly used in children with cow’s milk allergy (CMA). To be labeled hypoallergenic these Formulas must demonstrate in clinical studies that they don’t provoke reactions in 90% of subjects with confirmed CMA with 95% confidence when given in prospective randomized, double-blind, placebo-controlled challenge (DBPCFC) trials. The majority of available safety data on Aaf derived from patients with IgE-mediated CMA. Considering substantial differences in the immunologic mechanism and clinical presentation of non-IgE-mediated CMA it’s important to investigate the hypoallergenicity of these Formulas also in these patients. We prospectively assessed the tolerance to a new commercially available Aaf in children affected by IgE- or non-IgE-mediated CMA.

  • Clinical response to Amino Acid-Based Formula in neurologically impaired children with refractory esophagitis.
    Journal of pediatric gastroenterology and nutrition, 2002
    Co-Authors: Erasmo Miele, Annamaria Staiano, Arturo Tozzi, Renata Auricchio, Francesco Paparo, Riccardo Troncone
    Abstract:

    Objective: Chronic gastrointestinal symptoms and histologic changes of the esophagus unresponsive to standard treatments for gastroesophageal reflux disease (GERD) may be improved by the use of elemental Formulas. The aim of our study was to evaluate the efficacy of a dietary trial in neurologically impaired children unresponsive to medical and surgical therapy for GERD. Methods: Nine children (three boys and six girls; median age, 44 months; range, 13-180 months) affected by cerebral palsy associated with severe mental retardation and with long-standing history of GERD were fed the elemental Formula, Neocate, for a minimum of 4 weeks. Before and after the dietary trial, each child underwent endoscopy with esophageal biopsy and a cellobiose/mannitol sugar permeability test. The diagnosis of GERD was based on the microscopic changes of the esophagus. Results: Before the dietary trial, according to conventional histologic criteria, esophagitis was considered moderate in seven children and mild in two. Five of nine patients also had abnormal sugar permeability test results. During and after the dietary trial, seven of nine patients experienced resolution of their long-term symptom complaints. Furthermore, after the dietary trial, both endoscopic (P < 0.01) and histologic (P < 0.05) findings significantly improved. At 6-month follow-up, progressive reintroduction of individual dietary proteins, except for cow's milk protein, did not cause reappearance of the symptoms. Conclusions: In neurologically impaired children unresponsive to conventional antireflux treatments, a course of a highly restricted diet with an Amino Acid-Based Formula may bring an immediate and sustained, endoscopically and histologically proven improvement in long-standing gastrointestinal symptoms and esophagitis.

Harm Wopereis - One of the best experts on this subject based on the ideXlab platform.

  • A specific synbiotic-containing Amino Acid-Based Formula restores gut microbiota in non-IgE mediated cow’s milk allergic infants: a randomized controlled trial
    Clinical and Translational Allergy, 2019
    Co-Authors: Harm Wopereis, Rob Slump, Assad M. Butt, Diego G. Peroni, Adam T. Fox, David C. A. Candy, Marleen T J Van Ampting, Aysun Cetinyurek-yavuz, Yvan Vandenplas, Neil Shah
    Abstract:

    BackgroundAltered gut microbiota is implicated in cow’s milk allergy (CMA) and differs markedly from healthy, breastfed infants. Infants who suffer from severe CMA often rely on cow’s milk protein avoidance and, when breastfeeding is not possible, on specialised infant Formulas such as Amino-acid based Formulas (AAF). Herein, we report the effects of an AAF including specific synbiotics on oral and gastrointestinal microbiota of infants with non-IgE mediated CMA with reference to healthy, breastfed infants.MethodsIn this prospective, randomized, double-blind controlled study, infants with suspected non-IgE mediated CMA received test or control Formula. Test Formula was AAF with synbiotics (prebiotic fructo-oligosaccharides and probiotic Bifidobacterium breve M-16V). Control Formula was AAF without synbiotics. Healthy, breastfed infants were used as a separate reference group (HBR). Bacterial compositions of faecal and salivary samples were analysed by 16S rRNA-gene sequencing. Faecal analysis was complemented with the analysis of pH, short-chain fatty acids (SCFAs) and lactic acids.ResultsThe trial included 35 test subjects, 36 controls, and 51 HBR. The 16S rRNA-gene sequencing revealed moderate effects of test Formula on oral microbiota. In contrast, the gut microbiota was substantially affected across time comparing test with control. In both groups bacterial diversity increased over time but was characterised by a more gradual increment in test compared to control. Compositionally this reflected an enhancement of Bifidobacterium spp. and Veillonella sp. in the test group. In contrast, the control-fed infants showed increased abundance of adult-like species, mainly within the Lachnospiraceae family, as well as within the Ruminococcus and Alistipes genus. The effects on Bifidobacterium spp. and Lachnospiraceae spp. were previously confirmed through enumeration by fluorescent in situ hybridization and were shown for test to approximate the proportions observed in the HBR. Additionally, microbial activity was affected as evidenced by an increase of l -lactate, a decrease of valerate, and reduced concentrations of branched-chain SCFAs in test versus control.ConclusionsThe AAF including specific synbiotics effectively modulates the gut microbiota and its metabolic activity in non-IgE mediated CMA infants bringing it close to a healthy breastfed profile. Trial registration Registered on 1 May 2013 with Netherlands Trial Register Number NTR3979.

  • A specific synbiotic-containing Amino Acid-Based Formula restores gut microbiota in non-IgE mediated cow's milk allergic infants: A randomized controlled trial
    Clinical and translational allergy, 2019
    Co-Authors: Harm Wopereis, Rob Slump, Assad M. Butt, Adam T. Fox, David C. A. Candy, Aysun Cetinyurek-yavuz, Yvan Vandenplas, Diego Peroni, Marleen T. J. Van Ampting, Neil Shah
    Abstract:

    Altered gut microbiota is implicated in cow’s milk allergy (CMA) and differs markedly from healthy, breastfed infants. Infants who suffer from severe CMA often rely on cow’s milk protein avoidance and, when breastfeeding is not possible, on specialised infant Formulas such as Amino-acid based Formulas (AAF). Herein, we report the effects of an AAF including specific synbiotics on oral and gastrointestinal microbiota of infants with non-IgE mediated CMA with reference to healthy, breastfed infants. In this prospective, randomized, double-blind controlled study, infants with suspected non-IgE mediated CMA received test or control Formula. Test Formula was AAF with synbiotics (prebiotic fructo-oligosaccharides and probiotic Bifidobacterium breve M-16V). Control Formula was AAF without synbiotics. Healthy, breastfed infants were used as a separate reference group (HBR). Bacterial compositions of faecal and salivary samples were analysed by 16S rRNA-gene sequencing. Faecal analysis was complemented with the analysis of pH, short-chain fatty acids (SCFAs) and lactic acids. The trial included 35 test subjects, 36 controls, and 51 HBR. The 16S rRNA-gene sequencing revealed moderate effects of test Formula on oral microbiota. In contrast, the gut microbiota was substantially affected across time comparing test with control. In both groups bacterial diversity increased over time but was characterised by a more gradual increment in test compared to control. Compositionally this reflected an enhancement of Bifidobacterium spp. and Veillonella sp. in the test group. In contrast, the control-fed infants showed increased abundance of adult-like species, mainly within the Lachnospiraceae family, as well as within the Ruminococcus and Alistipes genus. The effects on Bifidobacterium spp. and Lachnospiraceae spp. were previously confirmed through enumeration by fluorescent in situ hybridization and were shown for test to approximate the proportions observed in the HBR. Additionally, microbial activity was affected as evidenced by an increase of l-lactate, a decrease of valerate, and reduced concentrations of branched-chain SCFAs in test versus control. The AAF including specific synbiotics effectively modulates the gut microbiota and its metabolic activity in non-IgE mediated CMA infants bringing it close to a healthy breastfed profile. Trial registration Registered on 1 May 2013 with Netherlands Trial Register Number NTR3979.

  • A specific synbiotic-containing Amino Acid-Based Formula in dietary management of cow's milk allergy : a randomized controlled trial
    Clinical and translational allergy, 2019
    Co-Authors: Adam T. Fox, Assad M. Butt, David C. A. Candy, Harm Wopereis, Yvan Vandenplas, Diego Peroni, Marleen T. J. Van Ampting, Manon M. Oude Nijhuis, Neil P. Shah, Christina E. West
    Abstract:

    Here we report follow-up data from a double-blind, randomized, controlled multicenter trial, which investigated fecal microbiota changes with a new Amino Acid-Based Formula (AAF) including synbiotics in infants with non-immunoglobulin E (IgE)-mediated cow’s milk allergy (CMA). Subjects were randomized to receive test product (AAF including fructo-oligosaccharides and Bifidobacterium breve M-16V) or control product (AAF) for 8 weeks, after which infants could continue study product until 26 weeks. Fecal percentages of bifidobacteria and Eubacterium rectale/Clostridium coccoides group (ER/CC) were assessed at 0, 8, 12, and 26 weeks. Additional endpoints included stool markers of gut immune status, clinical symptoms, and safety assessments including adverse events and medication use. The trial included 35 test subjects, 36 controls, and 51 in the healthy reference group. Study product was continued by 86% and 92% of test and control subjects between week 8–12, and by 71% and 80%, respectively until week 26. At week 26 median percentages of bifidobacteria were significantly higher in test than control [47.0% vs. 11.8% (p 

  • MOESM2 of A specific synbiotic-containing Amino Acid-Based Formula in dietary management of cow’s milk allergy: a randomized controlled trial
    2019
    Co-Authors: Adam Fox, Harm Wopereis, Neil Shah, Yvan Vandenplas, Diego Peroni, Marleen Van Ampting, Manon Oude Nijhuis, Assad Butt, David Candy, Christina West
    Abstract:

    Additional file 2: Figure S1. Box plot of exploratory markers in stools: (a) fecal sIgA, (b) ECP, (c) calprotectin, and (d) alpha-1-antitrypsin. The grey area represents the sample 25th to 75th percentile of the healthy subjects and the grey lines represent the minimum and maximum values of the healthy subjects (matched on age at Week 8 only). Horizontal line in box plot is the 50th percentile (median), whiskers of the box plots show the minimum and maximum values. The diamonds represent the mean values

  • Gut Microbiota Composition of Non-IgE Mediated Cow's Milk Allergic Infants before and after Dietary Management with a Synbiotics-Supplemented Amino Acid-Based Formula
    Journal of Allergy and Clinical Immunology, 2017
    Co-Authors: Harm Wopereis, Adam T. Fox, David C. A. Candy, Lucien F Harthoorn, Yvan Vandenplas, Diego Peroni, Marleen T. J. Van Ampting, Manon M. Oude Nijhuis, Louise J. Michaelis, Jan Knol
    Abstract:

    Gut Microbiota Composition of Non-IgE Mediated Cow's Milk Allergic Infants before and after Dietary Management with a Synbiotics-Supplemented Amino Acid-Based Formula

Bryan M Harvey - One of the best experts on this subject based on the ideXlab platform.

  • mineral intake and status of cow s milk allergic infants consuming an Amino acid based Formula
    Journal of Pediatric Gastroenterology and Nutrition, 2017
    Co-Authors: Bryan M Harvey, Lucien F Harthoorn, Simone R B M Eussen, Wesley A Burks
    Abstract:

    Data on the mineral status of infants with cow's milk allergy (CMA) consuming an Amino Acid-Based Formula (AAF) have not been published. The present study aims to assess mineral status of term infants age 0 to 8 months diagnosed with CMA receiving an AAF for 16 weeks. Serum concentrations of calcium, phosphorus, chloride, sodium, potassium, magnesium, and ferritin were determined in 82 subjects at baseline and in 66 subjects after 16 weeks on AAF using standard methods and evaluated against age-specific reference ranges. In addition to this, individual estimated energy and mineral intakes were compared to Adequate Intakes defined by the European Food Safety Authority and the US Institute of Medicine. The results of this study show that the AAF was effective in providing an adequate mineral status in infants with CMA. The vast majority of infants aged 0 to 6 months (Formula only) and aged 6 to 12 months (Formula and complementary foods) had adequate mineral intakes.

  • synbiotics supplemented Amino acid based Formula supports adequate growth in cow s milk allergic infants
    Applied Immunohistochemistry & Molecular Morphology, 2015
    Co-Authors: Wesley A Burks, Lucien F Harthoorn, Marleen T J Van Ampting, Manon Oude M Nijhuis, Jane Elizabeth Langford, Harm Wopereis, Steven B Goldberg, Brandon J Essink, Robert B. Scott, Bryan M Harvey
    Abstract:

    Background Children with cow's milk allergy (CMA) are at risk for inadequate nutritional intake and growth. Dietary management of CMA, therefore, requires diets that are not only hypoallergenic but also support adequate growth in this population. This study assessed growth of CMA infants when using a new Amino Acid-Based Formula (AAF) with prebiotics and probiotics (synbiotics) and evaluated its safety in the intended population. Methods In a prospective, randomized, double-blind controlled study, full-term infants with diagnosed CMA received either an AAF (control; n = 56) or AAF with synbiotics (oligofructose, long-chain inulin, acidic oligosaccharides, Bifidobacterium breve M-16V) (test; n = 54) for 16 wk. Primary outcome was growth, measured as weight, length and head circumference. Secondary outcomes included allergic symptoms and stool characteristics. Results Average age (±SD) of infants at inclusion was 4.5 ± 2.4 months. Both Formulas equally supported growth according to WHO 2006 growth charts and resulted in similar increases of weight, length and head circumference. At week 16, differences (90% CI) in Z-scores (test–control) were as follows: weight 0.147 (−0.10; 0.39, p = 0.32), length −0.299 (−0.69; 0.09, p = 0.21) and head circumference 0.152 (−0.15; 0.45, p = 0.40). Weight-for-age and length-for-age Z-scores were not significantly different between the test and control groups. Both Formulas were well tolerated and reduced allergic symptoms; the number of adverse events was not different between the groups. Conclusions This is the first study that shows that an AAF with a specific synbiotic blend, suitable for CMA infants, supports normal growth and growth similar to the AAF without synbiotics. This clinical trial is registered as NCT00664768.

  • O23 - Functional effects of an Amino-acid based Formula with synbiotics in cow’s milk allergic infants
    Clinical and Translational Allergy, 2014
    Co-Authors: Wesley Burks, Lucien F Harthoorn, Jane Elizabeth Langford, Steven B Goldberg, Brandon J Essink, Robert B. Scott, Marleen T. J. Van Ampting, Peck Y. Ong, Bryan M Harvey
    Abstract:

    Pre- and probiotics (synbiotics) are suggested to have beneficial effects on human health. This study describes effects of an Amino acid based Formula (AAF) with synbiotics in infants with cow’s milk allergy (CMA). In a prospective, randomized, double-blind controlled study, full term infants with diagnosed IgE and/or non-IgE mediated CMA received a commercially available AAF (NEO; n=56) or an AAF with synbiotics (neutral and acidic oligosaccharides, Bifidobacterium breve M-16V) (NEO-SYN; n=54) for 16 weeks. Primary outcome was growth and Formula tolerance; secondary outcomes were dermatological/respiratory allergic characteristics, and stool characteristics recorded in subject diaries and evaluated by a physician. Furthermore, adverse events and concomitant medications used during the study were reported. Average age of infants at inclusion was 4.5±2.4 months. Overall, NEO-SYN and NEO were equally tolerated and both supported normal growth. Both Formulas reduced allergic symptoms; SCORAD decreased in both groups with no significant differences in SCORAD change over 16 weeks between both groups. Softer and yellow/brown stools were reported more frequently in the NEO-SYN group compared to more dry and green/dark brown stools in the NEO group (week 0-2, p=0.035; week 2-4, p=0.010 for stool consistency). Furthermore, the NEO-SYN group had less subjects with reported infections (p=0.008) and less subjects receiving medication for functional gastrointestinal disorders (p=0.029) when compared with the NEO group. In addition the NEO-SYN group had a lower number of infants on antibiotics (p=0.049), especially amoxicillin (p=0.004). This study shows that an AAF with synbiotics is equally tolerated, supports normal growth and is similarly effective in the management of CMA symptoms compared to an AAF without synbiotics. Infants taking an AAF with this synbiotic blend have different stool characteristics, less reported infections and less antibiotic use, which suggests that addition of the synbiotics to an AAF improves resistance to infections and reduces specific medication use.

  • effects on growth and tolerance and hypoallergenicity of an Amino acid based Formula with synbiotics
    Pediatric Research, 2014
    Co-Authors: Bryan M Harvey, Lucien F Harthoorn, Jane Elizabeth Langford, Sherwin A Gillman, Todd D Green, Richard H Schwartz, Wesley A Burks
    Abstract:

    Effects on growth and tolerance and hypoallergenicity of an Amino acid–based Formula with synbiotics

  • Effects on growth and tolerance and hypoallergenicity of an Amino acid–based Formula with synbiotics
    Pediatric research, 2013
    Co-Authors: Bryan M Harvey, Lucien F Harthoorn, Jane Elizabeth Langford, Sherwin A Gillman, Todd D Green, Richard H Schwartz, A. Wesley Burks
    Abstract:

    Effects on growth and tolerance and hypoallergenicity of an Amino acid–based Formula with synbiotics